Evidence map›Paper›PMID 41547954›Full record

ArticleNPJ vaccines2026

Multi-antigen DNA vaccine targeting non-structural proteins confers robust T Cell-mediated protection against Zika virus.

Ryan Santos, Zelalem A Mekonnen, Arthur Eng Lip Yeow, Dawn M Whelan, Zahraa Al-Delfi, Nicholas S Eyre, Michael R Beard, Dan H Barouch, David H O'Connor, Makutiro G Masavuli and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ryan Santos *Viral Immunology Group, Adelaide Medical School, The University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA, Australia.
Zelalem A Mekonnen *Viral Immunology Group, Adelaide Medical School, The University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA, Australia.
Arthur Eng Lip YeowViral Immunology Group, Adelaide Medical School, The University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA, Australia.
Dawn M WhelanViral Immunology Group, Adelaide Medical School, The University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA, Australia.
Zahraa Al-DelfiViral Immunology Group, Adelaide Medical School, The University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA, Australia.
Nicholas S EyreMolecular Virology Group, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
Michael R BeardResearch Centre for Infectious Diseases, School of Biological Sciences, University of Adelaide, Adelaide, SA, Australia.
Dan H BarouchCentre for Virology and Vaccine Research, Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston, MA, USA.
David H O'ConnorDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Makutiro G MasavuliViral Immunology Group, Adelaide Medical School, The University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA, Australia.
Branka Grubor-BaukViral Immunology Group, Adelaide Medical School, The University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA, Australia. branka.grubor@adelaide.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Zika virus (ZIKV) vaccine development has been hindered by the risk of antibody-dependent enhancement (ADE), particularly in dengue-endemic regions, where sub-neutralizing antibodies can exacerbate disease severity. T cell-based vaccines targeting non-structural (NS) antigens represent a safer alternative that bypasses this risk. Using immunocompetent BALB/c mice, we performed high-resolution in vivo mapping of ZIKV specific CD8⁺ and CD4⁺ T cell responses following ZIKV

Identifiers

PMID41547954
PMCPMC12858821

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.